Genomic Valley Biotech Ltd
₹ 40.3
1.61%
13 Aug
- close price
About
Incorporated in 2001, Genomic Valley Biotech Ltd is in the business of Horticultural and Agricultural products, and is also adding activities in Human Genomic[1]
Key Points
- Market Cap ₹ 12.3 Cr.
- Current Price ₹ 40.3
- High / Low ₹ 108 / 38.6
- Stock P/E 49.2
- Book Value ₹ 12.7
- Dividend Yield 0.00 %
- ROCE 11.8 %
- ROE 9.68 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 3.16 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.4% over last 3 years.
- Company has high debtors of 960 days.
- Promoter holding has decreased over last 3 years: -21.1%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.09 | 0.03 | 0.11 | 0.44 | 0.59 | 0.99 | 0.85 | 0.21 | 0.07 | 2.72 | 0.17 | 0.84 | 0.78 | |
| 0.08 | 0.07 | 0.54 | 0.48 | 0.49 | 0.57 | 0.30 | 0.34 | 0.45 | 1.84 | 0.15 | 0.40 | 0.45 | |
| Operating Profit | 0.01 | -0.04 | -0.43 | -0.04 | 0.10 | 0.42 | 0.55 | -0.13 | -0.38 | 0.88 | 0.02 | 0.44 | 0.33 |
| OPM % | 11.11% | -133.33% | -390.91% | -9.09% | 16.95% | 42.42% | 64.71% | -61.90% | -542.86% | 32.35% | 11.76% | 52.38% | 42.31% |
| 0.01 | 0.07 | 0.16 | 0.01 | 0.03 | 0.01 | 0.01 | 0.00 | 0.50 | -0.22 | 0.00 | 0.00 | 0.01 | |
| Interest | 0.01 | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | 0.18 | 0.18 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.01 | 0.05 | 0.04 | 0.08 | 0.19 | 0.18 | 0.19 | 0.08 | 0.01 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.01 | -0.01 | -0.34 | -0.07 | 0.05 | 0.24 | 0.20 | -0.50 | 0.00 | 0.65 | 0.02 | 0.44 | 0.34 |
| Tax % | 0.00% | 0.00% | -2.94% | 0.00% | 40.00% | 0.00% | -40.00% | 12.00% | 0.00% | 0.00% | 20.45% | ||
| 0.00 | -0.01 | -0.33 | -0.07 | 0.03 | 0.23 | 0.29 | -0.56 | -0.01 | 0.65 | 0.02 | 0.36 | 0.25 | |
| EPS in Rs | 0.00 | -0.03 | -1.08 | -0.23 | 0.10 | 0.75 | 0.95 | -1.83 | -0.03 | 2.13 | 0.07 | 1.18 | 0.82 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 40% |
| 5 Years: | 0% |
| 3 Years: | 129% |
| TTM: | 189% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 44% |
| 5 Years: | 4% |
| 3 Years: | 42% |
| TTM: | 92% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 6% |
| 1 Year: | -33% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 2% |
| 3 Years: | 12% |
| Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
| Reserves | 1.85 | 1.84 | 1.51 | 1.44 | 1.47 | 1.71 | 1.99 | 1.43 | -0.18 | 0.47 | 0.49 | 0.84 |
| 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 1.48 | 1.48 | 1.55 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.61 | 0.80 | 0.73 | 0.78 | 1.41 | 0.94 | 1.49 | 1.59 | 0.92 | 0.90 | 0.79 | 0.47 | |
| Total Liabilities | 6.26 | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 |
| 3.02 | 3.15 | 3.18 | 3.63 | 4.12 | 4.31 | 4.47 | 5.86 | 1.75 | 0.00 | 0.00 | 0.01 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.38 | 0.49 | 0.49 | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.55 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| 3.24 | 2.74 | 2.75 | 2.39 | 2.18 | 2.38 | 3.05 | 1.27 | 2.04 | 4.42 | 4.31 | 4.35 | |
| Total Assets | 6.26 | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.09 | -0.69 | 0.35 | 0.87 | -1.04 | 0.44 | 1.48 | -2.13 | -0.78 | -0.02 | 0.03 | |
| 0.01 | -0.65 | 0.53 | -0.31 | -0.91 | 0.37 | -0.47 | -1.58 | 3.67 | 1.52 | -0.02 | 0.01 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.73 | 0.00 | 0.07 | -1.55 | -0.70 | 0.00 | 0.00 | |
| Net Cash Flow | 0.01 | -0.56 | -0.16 | 0.04 | -0.04 | 0.06 | -0.04 | -0.03 | -0.01 | 0.04 | -0.04 | 0.04 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 960.30 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 486.67 | ||||||
| Days Payable | 17.38 | |||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 1,429.58 |
| Working Capital Days | 7,746.11 | -8,881.67 | -1,659.09 | -514.32 | -804.24 | 55.30 | -176.06 | -1,251.43 | 4,849.29 | 221.42 | 4,530.29 | 916.85 |
| ROCE % | 0.41% | 0.35% | -5.84% | -0.57% | 0.57% | 4.17% | 5.96% | -5.10% | -8.54% | 28.48% | 0.57% | 11.83% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Aug - Newspaper Advertisement regarding publication of unaudited financial result of the company for the quarter ended 30 June, 2025.
-
Re-Appointment Of Mr. Yogesh Agrawal As Chairman & Managing Director Of The Company For The Period Of Five (5) Years With Effect From 07.09.2025
7 Aug - Q1 FY2025-26 results approved; MD re-appointed for 5 years; new secretarial and internal auditors appointed.
-
Appointment Of Internal Auditor For The FY 2025-26.
7 Aug - Approved Q1 FY25 unaudited results; appointed secretarial, internal auditors; re-appointed MD for 5 years.
-
Appointment Of Secretarial Auditor
7 Aug - Approved Q1 FY25 unaudited results; appointed secretarial and internal auditors; re-appointed MD for 5 years.
-
Unaudited Financial Results For Quarter Ended June 30, 2025.
7 Aug - Q1 FY25 unaudited results approved; new auditors appointed; MD re-appointed for 5 years from Sept 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1][2]
GVBL, with its experience in Next-Generation Sequencing (NGS), oncology, and Artificial Intelligence (AI), provides biotechnology
and healthcare solutions. The company provides personalized therapy options, helping doctors with decision-making support and identifying effective treatments, and aims to transform oncology research and diagnostics.
The company also provides Research Process Outsourcing (RPO) services to global researchers